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Abstract 
Mouse models of Alzheimer’s disease (AD) are valuable but do not fully recapitulate human AD pathology, such 
as spontaneous Tau fibril accumulation and neuronal loss, necessitating the development of new AD models. 
The transgenic (TG) TgF344-AD rat has been reported to develop age-dependent AD features including 
neuronal loss and neurofibrillary tangles, despite only expressing APP and PSEN1 mutations, suggesting an 
improved modelling of AD hallmarks. Alterations in neuronal networks as well as learning performance and 
cognition tasks have been reported in this model, but none have combined a longitudinal, multimodal approach 
across multiple centres, which mimics the approaches commonly taken in clinical studies. We therefore aimed 
to further characterise the progression of AD-like pathology and cognition in the TgF344-AD rat from 
young-adults (6 months (m)) to mid- (12 m) and advanced-stage (18 m, 25 m) of the disease. 
Methods: TgF344-AD rats and wild-type (WT) littermates were imaged at 6 m, 12 m and 18 m with 
[18F]DPA-714 (TSPO, neuroinflammation), [18F]Florbetaben (Aβ) and [18F]ASEM (α7-nicotinic acetylcholine 
receptor) and with magnetic resonance spectroscopy (MRS) and with (S)-[18F]THK5117 (Tau) at 15 and 25 m. 









NeuN, NeuroChrom) and Tau (S)-[18F]THK5117 autoradiography, immunohistochemistry and Western blot 
were also performed. 
Results: [18F]DPA-714 positron emission tomography (PET) showed an increase in neuroinflammation in TG 
vs wildtype animals from 12 m in the hippocampus (+11%), and at the advanced-stage AD in the hippocampus 
(+12%), the thalamus (+11%) and frontal cortex (+14%). This finding coincided with strong increases in brain 
microgliosis (CD11b) and astrogliosis (GFAP) at these time-points as assessed by immunohistochemistry. In 
vivo [18F]ASEM PET revealed an age-dependent increase uptake in the striatum and pallidum/nucleus basalis of 
Meynert in WT only, similar to that observed with this tracer in humans, resulting in TG being significantly lower 
than WT by 18 m. In vivo [18F]Florbetaben PET scanning detected Aβ accumulation at 18 m, and 
(S)-[18F]THK5117 PET revealed subsequent Tau accumulation at 25m in hippocampal and cortical regions. Aβ 
plaques were low but detectable by immunohistochemistry from 6 m, increasing further at 12 and 18 m with 
Tau-positive neurons adjacent to Aβ plaques at 18 m. NeuroChrom (a pan neuronal marker) 
immunohistochemistry revealed a loss of neuronal staining at the Aβ plaques locations, while NeuN labelling 
revealed an age-dependent decrease in hippocampal neuron number in both genotypes. Behavioural 
assessment using the novel object recognition task revealed that both WT & TgF344-AD animals discriminated 
the novel from familiar object at 3 m and 6 m of age. However, low levels of exploration observed in both 
genotypes at later time-points resulted in neither genotype successfully completing the task. Deficits in social 
interaction were only observed at 3 m in the TgF344-AD animals. By in vivo MRS, we showed a decrease in 
neuronal marker N-acetyl-aspartate in the hippocampus at 18 m (-18% vs age-matched WT, and -31% vs 6 m 
TG) and increased Taurine in the cortex of TG (+35% vs age-matched WT, and +55% vs 6 m TG). 
Conclusions: This multi-centre multi-modal study demonstrates, for the first time, alterations in brain 
metabolites, cholinergic receptors and neuroinflammation in vivo in this model, validated by robust ex vivo 
approaches. Our data confirm that, unlike mouse models, the TgF344-AD express Tau pathology that can be 
detected via PET, albeit later than by ex vivo techniques, and is a useful model to assess and longitudinally 
monitor early neurotransmission dysfunction and neuroinflammation in AD. 
Key words: Alzheimer’s disease, animal models, positron emission tomography, magnetic resonance 
spectroscopy, neuroinflammation 
Introduction 
Alzheimer’s disease (AD) is a major global 
health problem, affecting approximately 50 million 
people worldwide [1]. Yet, our understanding of the 
mechanisms leading to progressive neuro-
degeneration and dysfunction in AD remains 
incomplete. Clinical AD pathology is characterised by 
progressive amyloid-beta plaque (Aβ) deposition, 
neurofibrillary tangle (NFT) formation due to Tau 
protein aggregation and neuronal loss. However it 
has become clear that AD is a complex and 
multi-faceted disease involving not only Aβ and Tau 
pathology but also chronic activation of microglia and 
astrocytes [2, 3], metabolic dysfunction [4], and 
altered cholinergic activity [5]. Moreover, it is 
hypothesised that pathological alterations may begin 
many years before AD symptoms become apparent 
making early diagnosis and disease management 
challenging. Therefore, a better understanding of the 
pathophysiology underlying AD manifestation and 
progression is urgently needed to improve diagnosis 
and treatment of this devastating disorder. 
Preclinical investigations using animal models 
are an essential part of the arsenal of tools to probe 
specific disease mechanisms and test the efficacy of 
therapeutic and diagnostic strategies within a living 
organism. Genetically modified mouse models are 
commonly used in AD research, allowing the 
investigation and confirmation of pathology induced 
by human familial AD mutations associated with 
amyloid precursor protein (APP) and presenilin 1 or 2 
(PS1/PS2). These mouse models develop AD-like 
amyloid pathology such as age-dependent increases 
in Aβ plaque deposition, soluble and insoluble 
Aβ40/Aβ42 levels, and cerebral amyloid angiopathy 
(CAA) [6]. Although all these transgenes-induced AD 
models are modelling the familial rather than the 
sporadic AD, until models of spontaneous AD exist, 
these models are beneficial in gaining a better 
understanding of amyloidogenic pathways and other 
disease processes. However, most of these models do 
not develop neuronal loss or NFTs without the 
integration of a Tau transgene. While some amyloid 
models have been reported to express increased 
hyperphosphorylated Tau, Tau aggregates similar to 
NFTs are not observed [7, 8]. This lack of concordance 
with the clinical situation may be in part responsible 
for the low success in translatability of AD therapies. 
Hence, there has been a drive for improved animal 
models, which encompass the multiple pathological 
features observed in clinical AD. Consequently, 
transgenic AD rat models have been developed, with 
rats having the additional advantage over mice of a 
larger brain size for in vivo imaging and improved 
possibility for behavioural testing [9]. Early genetic rat 
models were unsuccessful in precipitating 
extracellular amyloid plaques [10]; later attempts 





yielded better results but most developed only Aβ 
plaques (for review see Do Carmo and Cuello, 2013 
[11]). However, a more recent model, the TgF344-AD 
rat, described by Cohen et al. [12], demonstrated an 
age-dependent progressive amyloid pathology 
including plaque deposition, CAA, inter-neuronal 
and soluble amyloid in regions associated with and at 
levels comparable to that observed in clinical AD. 
Moreover, NFT-like Tau pathology as well as 
neuronal loss and neuroinflammation were also 
reported, overall providing a better representation of 
AD-like pathology. In their study Cohen et al. 
characterised the model at 6, 16 and 26 months (m) of 
age. Increased Aβ40 was reported as early as 6 m with 
cognitive deficits by 15 m and NFT deposition by 16 
m. Finally, increased microglial and astrocyte 
activation were detected ex vivo as early as 6 m of age. 
Since then, various deficits and dysfunctions have 
been reported at different ages in these rats including 
alterations in hippocampal and cortical neuro-
transmission [13-16], neurovascular dysfunction [17], 
behavioural deficits [18-21], functional connectivity 
alterations [22-24] and blood-brain barrier alterations 
[25]. Hence this model seems to be a good candidate, 
yet some important parameters have not been 
investigated and questions remain as to whether this 
is a useful model to investigate longitudinal in vivo 
markers of AD. 
Here we take an in vivo multi-modal approach to 
characterise AD development and progression in 
TgF344-AD and wildtype (WT) rats from early to 
more advanced stages of the disease (6 to 25 m), 
including non-invasive longitudinal imaging, ex vivo 
immunohistochemical analysis and cognitive 
assessments. Specifically, and for the first time, 
[18F]DPA-714, [18F]ASEM, [18F]Florbetaben ([18F]AV-1) 
and (S)-[18F]THK5117 PET imaging were performed to 
assess neuroinflammation, the acetylcholine system, 
Aβ plaque deposition and Tau aggregates 
respectively. Additionally, magnetic resonance 
spectroscopy (MRS) was performed to assess 
metabolite alterations associated with neuronal 
dysfunction and inflammation. Altogether, those in 
vivo measurements, combined with ex vivo 
immunohistochemical assessments are providing 
novel and wide-ranging information about the 
neuropathological characteristics and utility of this 
model. 
Materials and Methods 
Animals 
Two male and two female WT Fischer and 
TgF344-AD rats with the APPswe and PS1Δe9 mutations 
were purchased from the laboratory of Prof T. Town 
(University of Southern California) and were set up as 
breeding pairs, housed in the Biological Services Unit 
at the University of Manchester. Genotyping was 
outsourced to Transnetyx®. All animals were housed 
in groups of 2-4 per cage with individual ventilation, 
environmental enrichment, constant access to food 
and water and a 12:12 hour cycle of light and dark. 
In vivo experiments were conducted across three 
centres: University of Manchester (UK), University of 
Tours (France) and University of Turku (Finland) and 
animals were housed and fed in the same conditions 
as in Manchester. All experiments carried out at the 
University of Manchester were performed in 
accordance with the Animal Scientific Procedures Act 
1986, following internal ethical review. Breeding pairs 
from this colony were sent to the University of Tours 
and University of Turku where rats were bred for 
investigation of amyloid ([18F]Florbetaben), α7-nAchR 
([18F]ASEM) and Tau ((S)-[18F]THK5117). In Tours, 
animals were treated in accordance with the 
European Community Council Directive 2010/63/EU 
for laboratory animal care and the experimental 
protocol was validated by the Regional Ethical 
Committee (Authorization n°4795.03). Genotyping 
was outsourced to Charles River GEMS (France). In 
Turku all animal experiments were approved by the 
Regional State Administrative Agency for Southern 
Finland (ESAVI/3899/04.10.07/2013 and ESAVI/ 
4499/04.10.07/2016), and animal care complied with 
the principles of the laboratory animal care and with 
the guidelines of the International Council of 
Laboratory Animal Science. 
Details of numbers of animals for each 
experiment are provided below and in Tables S1-S4. 
Survival curves and mortality/exclusions are shown 
for the University of Manchester cohort in Table S4 
and Figure S1. 
Study Design 
Animals bred at the University of Manchester 
underwent behavioural testing, MRS, [18F]DPA-714 
PET, and immunohistochemistry studies. N number 
per group were based on power analysis of our own 
or previously published data with α = 0.05 and 
β = 0.95 [12, 21, 26-30]. Various parameters including 
moderate increases in neuroinflammation, Aβ and 
Tau have been reported in the Tg-F344-AD rat via 
immunohistochemistry at 6, 16 and 26 m [12]. Thus, 
[18F]DPA-714 PET was performed at 6 m, 12 m and 18 
m to non-invasively assess longitudinal alterations in 
neuroinflammation in WT and TG rats from early to 
advanced disease. Similarly, these time-points were 
used for MRS imaging and behavioural assessment. In 
particular, the 12 m time-point was chosen because 
we wanted to address the progression in the critical 





prodromal stage of the disease and from Cohen et al. 
[12] it seemed clear that AD-like pathology was 
already quite advanced by 16 m of age. Brain tissue 
was harvested in a subset of rats at each time-point 
(Table S1) for ex vivo analysis i) between 5m 3 weeks 
and 7m 2 weeks (referred to as the 6 m time-point; 
WT: 208 ± 24 days, n = 5 (mean ± SD); TG: 203 ± 21 
days, n = 8), ii) between 11m 3 weeks and 13 m 2 
weeks (12 m time-point; WT: 391 ± 23 days, n = 5; TG: 
389 ± 16 days, n = 6) and iii) between 18 m 2 weeks 
and 19m 3 weeks (18 m time-points; end-point for 
animals from the longitudinal study and few 
additional animals; WT: 585 ± 11 days, n = 13; TG: 591 
± 14 days, n = 11) (See Tables S1 and S2 for full 
details). There was a minimum gap of one week 
between anaesthetising animals for imaging and 
conducting behavioural tests. Imaging experiments 
were carried out during the light phase of day. 
Behavioural assessments begun at the end of the dark 
phase (4-7 AM) as the rats were more active and 
exploratory behaviour was increased at this time. 
WT and TG males (n = 8 per group) bred at the 
University of Tours were enrolled in [18F]Florbetaben 
and [18F]ASEM PET studies at 6, 12 and 18 m (for 
more details see Table S3). 
Tau pathology was assessed in 3 WT and 4 (one 
animal died at 24 months of age) TG females bred at 
the University of Turku using (S)-[18F]THK5117 PET 
at 15 and 25 m and ex vivo autoradiography at 25m. 
Tau studies were conducted at later time-points 
owing to previous findings indicating NFT-like Tau 
deposition in these rats from a mid-disease state (i.e., 
16 m) [12]. At 15 m (457 ± 9 days) rat weights were WT 
295 ± 5g and TG 302 ± 28g. At 25 m (748 ± 11 days) rat 
weights were WT 339 ± 37g and TG 340 ± 6g. 
PET Acquisition and Analysis 
[18F]DPA-714 PET 
To assess in vivo neuroinflammatory status 
[18F]DPA-714 PET was performed in WT and TG rats 
at 6, 12 and 18 m. [18F]DPA-714 was synthesized as 
previously described [31]. Animals underwent 
anaesthesia (1.5-2.5% isoflurane in a 30%/70% 
02/NO2 mixture at 1.2 l/min), tail vein cannulation, 
[18F]DPA-714 injection (33.1 ± 6.8 MBq) and 60 min 
dynamic PET/CT imaging. Imaging was carried out 
on a Siemens Inveon® PET/CT scanner and image 
reconstruction was performed as previously 
described [26, 27] (see Suppl. Material for more 
details). Skeletal and brain regions were defined 
manually in the CT images using Brainvisa and 
Anatomist software (http://brainvisa.info) to register 
PET-CT images with a MRI template; ROIs were 
quantified in Brainvisa by applying a rat MRI 
template adapted from Schwarz and colleagues [32]. 
Co-registration with a MRI atlas seem appropriate as 
Anckaerts et al. [22] did not report any age-dependent 
genotype-specific cortical atrophy or ventricular 
enlargement in the TG groups. ROIs included: 
entorhinal cortex, cingulate cortex, frontoparietal 
motor and somatosensory cortex, frontal cortex, 
temporal cortex, hippocampus, thalamus, 
hypothalamus and striatum. For the PET 
quantification the summed frames from 20 to 60 
(Figure S3A) min were used to calculate the uptake 
values normalised to cerebellum (NUVCb). The 
cerebellum was chosen as it is routinely used 
(clinically and preclinically) as a pseudo-reference 
region for TSPO-PET quantification in Alzheimer’s 
disease populations [26, 29, 33-36]. 
[18F]Florbetaben and [18F]ASEM PET 
[18F]florbetaben and [18F]ASEM PET were 
performed to assess respectively amyloid burden and 
α7 nicotinic acetylcholine receptor (α7-nAchR) 
density in WT and TG rats at 6, 12 and 18 m (see Table 
S3). [18F]Florbetaben [37] and [18F]ASEM [30] were 
synthesized as described previously. Anaesthetised 
animals (1.5-2% isoflurane in 1.5-2 L/min of O2) were 
scanned over 51 min for [18F]Florbetaben and 61 min 
for [18F]ASEM on a superArgus PET/CT system 
(Sedecal, Spain) according to Sérrière et al. [29] (for 
more details see Suppl. Material). Before PET 
acquisition, a 5 min CT scan was acquired for 
attenuation correction. Animals received a bolus 
injection of 37 MBq/350 g body weight of 
[18F]Florbetaben or [18F]ASEM in a saline solution via 
the tail vein. Images were analysed using PMOD 
(3.403, PMOD Technologies, Zurich, Switzerland). 
Partial volume effect correction was applied on all 
PET images which were co-registered to the Schiffer 
rat brain MRI template for regions of interest (ROI) 
analysis. Normalised uptake values (NUV) were 
calculated using the brainstem as reference region for 
[18F]Florbetaben (last 3 frames, 43-51 min acquisition, 
Figure S3B) [38] and cerebellum for [18F]ASEM [39] 
(last 6 frames, 49-61 min acquisition, Figure S3C). 
(S)-[18F]THK5117 PET and autoradiography 
To assess Tau deposition, (S)-[18F]THK5117 PET 
was performed in WT and TG rats at 15 and 25m. 
(S)-[18F]THK5117 was synthesized as previously 
described [40]. Prior to PET acquisition, a CT scan was 
acquired for attenuation correction. The rats were 
anesthetised with 2.5% isoflurane in a 30%/70% 
O2/NO2 mixture at 400-500 mL/min and then injected 
with a bolus injection of (S)-[18F]THK5117 (23.7 ± 
3.0 MBq) and 60 min dynamic scans were acquired 
using a Siemens Inveon® PET/CT scanner and 
reconstructed with OSEM-3D. PET images were 





pre-processed and co-registered to the Schiffer rat 
brain MRI template for ROI analysis (for more details 
see Suppl. Material). Following the final in vivo scan, 
the brains were quickly removed and frozen in 
isopentane (2-methylbutane; Sigma-Aldrich) on dry 
ice to perform ex vivo autoradiography studies. 
Coronal sections (20 μm) were obtained using a 
cryomicrotome (Leica CM3050S) and collected on a 
glass slide (Superfrost Ultra Plus; Thermo Fisher). The 
slides were exposed to an image plate (Fuji BAS 
Imaging Plate TR2025; Fuji Photo Film Co., Ltd.) for 4 
hours. 
For the PET quantification the summed frames 
from 30 to 40 min were used (Figure S3D); PET and 
autoradiography data are expressed as standard 
uptake values normalised to striatum (NUVstr). ROIs 
included: temporal-auditory, piriform, frontal, 
frontoparietal and cingulate cortices, hippocampus, 
thalamus, pons, cerebellum, hypothalamus and 
striatum. PET and autoradiography quantification 
were performed as previously described [41]. 
Magnetic Resonance Spectroscopy Acquisition 
and Analysis 
To assess metabolite profile, single voxel MRS 
was performed in the full hippocampus (2 × 9 × 3 
mm3), right hippocampus (2 × 4.5 × 3 mm3), thalamus 
(2.5 × 8 × 3 mm3), hypothalamus (2 × 3 × 3 mm3) and 
cortex (1.2 × 3 × 3 mm3) in TG and WT rats at 6, 12 and 
18 m of age (for localisation of the voxel for each brain 
region, see Figure S2). Isoflurane (2-3%) in oxygen 
(2L/min) was used to anesthetise and maintain rats. 
MRI and MRS were performed and analysed as 
previously described [26, 42] (see Suppl. Material for 
more details). Respiratory rate (65-80 breaths per min) 
and temperature (36.5-37 °C) were monitored and 
maintained throughout by altering respectively the 
anaesthesia and hot air supply. Metabolites are 
expressed as amplitude of institutional units relative 
to water. 
Immunohistochemistry 
For full details of Immunohistochemistry 
protocols, please see Suppl. Material. For all 
immunohistochemical analysis, the observers were 
blinded to the genotype and age-group of the animals, 
having only access to the animal number given at 
birth to each animal until all images were captured 
and analysed. However, it must be noted that the 
presence of Aβ plaques and associated microglial 
activation and astrogliosis were obvious when 
looking at the brain sections under a microscope. 
Number of animals used for each quantitative 
immunohistochemistry can be found in Table S5. 
Immunofluorescence for GFAP & CD11b, NeuN, 
Neurochrom and amyloid 
Animals were culled and brain were processed 
and cut as described previously [26, 27] (see Suppl. 
Material for more details). 
Immunohistochemistry was carried out on TG 
and WT 20 µm thick frozen brain sections (n = 5-9 per 
group, see Table S5) to visualise CD11b (microglial 
marker), GFAP (astrocytic marker), NeuN and 
Neurochrom (neuronal markers), and 6E10 (Aβ 
marker) as previously described [26] (for more details 
see Suppl. Material). 
Three to five images from 2-4 brain sections 
spanning between 1 and 2.86 mm lateral of Bregma 
were collected for each brain structure (hippocampus, 
thalamus and cortex) per animal. Image were 
collected on an Olympus BX51 upright microscope 
using 10×/0.30 or 20×/0.50 UPlanFLN objectives and 
captured using a Retiga 6000 Color camera through 
QCapture Pro 7 Software (QImaging Inc.). Specific 
band pass filter sets were used to prevent bleed 
through from one channel to the next. 
6E10 slides were scanned using a 3D Histec 
Pannoramic250 slide scanner and 1-4 snapshots per 
brain area of interest were taken using 3D Histec 
CaseViewer software. All snapshots were analysed 
using Fiji [43] (for full details see Suppl. Material). 
Chromogenic NeuN immunohistochemistry and 
analysis 
Sagittal sections were stained with rabbit 
anti-NeuN and Vector DAB HRP substrate (For full 
details of protocol see Suppl. Material). 
Amyloid Thioflavin-S staining and Tau 
immunohistochemistry 
Because our attempt to perform immunohisto-
chemistry for Tau using snap-frozen brain sections 
failed, we looked for PFA-perfused-fixed brains from 
one of our partners of the INMiND consortium. 
Perfused-fixed brains from 18 m old animals were a 
generous gift from Dr Guadalupe Soria (IDIBAPS, 
Barcelona, Spain) and were used for Phospho-Tau 
immunohistochemistry and amyloid Thioflavin-S 
staining. PFA-perfused-fixed brains were 
cryoprotected in 30% sucrose, sectioned into 30 µm 
thick sagittal sections using a Leica frozen microtome 
and stored as free-floating brain sections at 4 °C in 
PBS/0.3% azide. Phospho-Tau and Thioflavin-S 
co-staining: sections were permeabilised by 
incubating with 0.3% Triton-X 100/PBS then 
endogenous peroxidase was quenched in 0.5% H2O2 
for 30 min, and blocked in 2.5% normal horse serum 
(MP-7422, Vector Laboratory) followed by incubation 
with AT8, CP13 or PHF-1 primary antibody overnight 





at 4°C. Secondary Anti-Mouse IgG (MP-7422, Vector 
Laboratory) was applied for 30 min, followed by 
peroxidase substrate solution (SK-4105, Vector 
Laboratory) until desirable stain intensity developed. 
Sections were then incubated in 1% Thioflavin-S 
(T1892, SIGMA) solution for 7 min and washed with 
70% Ethanol, before mounting with Fluoromount-G 
medium (Southern Biotech). 
The entire hippocampus was imaged in each 
section using an EVOS FL Auto microscope (Life 
Technologies) with a ×20 objective, by area defined 
serial scanning (n = 3 per genotype). The image was 
processed using EVOS FL Auto Cell Imaging System 
and Adobe Photoshop CS6. 
Tau Western blot analysis 
Approximately 100 mg of cortex tissue was 
homogenised in 1 mL cold RIPA buffer as described 
previously [44]. The protein sample for Tau 
expression analysis was extracted from cortical tissue 
homogenate then lysed in Tau Dye. Lysed protein 
was boiled for 5 min at 95 °C. Next, Western blotting 
was performed using the SDS-PAGE gel and 
nitrocellulose membrane, with 50 µg protein loaded 
for each sample. CP13, PHF-1, DA9 and HSPA9 
primary antibodies were used (for more details see 
Table S6). Protein bands were visualized using 
enhanced chemiluminescence. Imaging was 
performed using the BIO-RAD ChemiDoc MP 
imaging system and protein expression bands were 
analysed by Image Lab software (BIO-RAD) (for more 
details see Suppl. Material). 
Behaviour 
The background strain (Fischer 344) used to 
generate the TgF344-AD has been reported to be 
highly anxious and proved to be so in our hands 
(avoidance, agitated when handled, vocalising, biting) 
[45, 46]. We thus ensured that animals were 
extensively handled prior to behavioural testing (see 
details in Suppl. Material). 
Novel Object Recognition Test 
To assess short-term non-associative working 
memory, a novel object recognition (NOR) test was 
carried out in WT (n = 9-10) and TG (n = 9-11; see 
Table S1 for details) rats at 3, 6, 12 and 18 m as 
previously described [47]. In brief, NOR tests were 
performed in 3% light, and involved acquisition, 
delay and retention phases of 3 min each. Time spent 
exploring the novel and familiar objects in the 
retention phase was used to quantify the 
discrimination index (DI) for each animal, defined as 
the novel minus the familiar time divided by the total 
time, giving values ranging from -1 to +1. Animals 
were excluded from analysis if side bias was 
displayed in the acquisition phase (> 60% time on one 
side) or if they did not demonstrate exploratory 
behaviour towards any objects in the retention phase 
(< 2s cut-off; 3 m: 2 TG; 6 m: 2 WT and 1 TG; 12 m: 
2 WT and 3 TG; and 18 m: 3 WT and 1 TG were 
excluded). 
Social Interaction Test 
A social interaction test was used to assess 
anxiety-like behaviour [48] in the WT (n = 9) and TG 
rats (n = 9-10; see Table S1 for details) at 9, 12, 15 and 
18 m. This test was carried out in 45% light. All rats 
were age and weight matched to avoid/minimise 
dominance and fighting behaviour. In brief, a test rat 
and an unfamiliar wildtype conspecific rat were 
placed in an arena for 10 min with an inanimate object 
(e.g. metal can or plastic bottle) in the centre. Time 
spent sniffing, following, and avoiding the conspecific 
animal as well as exploring the central object were 
quantified and data expressed as a discrimination 
index (see above). Arenas were cleaned with 70% 
ethanol in between trials. 
Statistical analysis 
The data were statistically analysed using 
GraphPad® Prism™ (v8.4, GraphPad Software, Inc., 
San Diego, California USA). 
Shapiro-Wilk normality test was carried out for 
raw exploration times to assess side bias and, 
depending on the normality of the distribution, either 
t-tests or Wilcoxon tests were used. Survival rate of 
the University of Manchester cohort was analysed 
using a Log-rank Mantel-Cox test. Mixed model 
effects analysis was used to assess alterations in DI in 
the NOR test. T-tests were used to investigate time 
spent exploring familiar and novel objects as well as 
social interaction behaviours in WT and TG animals at 
individual time-points. One-way ANOVA was used 
to assess levels of exploration over time in each group. 
Mixed model effects analysis was used to assess 
the effect of genotype and age (as repeated factor) and 
possible interaction on MRS metabolites levels and 
[18F]DPA-714 and (S)-[18F]THK5117 PET NUV values 
in WT and TG. [18F]ASEM PET NUV were analysed 
using 2-way ANOVA to assess the effect of genotype 
and age (as repeated factor) and possible interaction. 
Normality of the CD11b, GFAP, NeuN and Aβ 
immunohistochemistry quantitative data was 
analysed using d'Agostino and Pearson test and if 
significant, outliers were removed. Only GFAP in the 
temporal/posterior cingulate cortex and CD11b and 
GFAP in the thalamus did not pass the normality test 
and outliers were removed (see Table S5). 
Immunohistochemistry quantitative data were 
analysed using 2 way-ANOVA (genotype and age). 





If a significant effect and/or interaction were 
found with the mixed model effects analysis or 
ANOVA, a post-hoc Sidak test was performed to 
determine group differences. 
Autoradiographic data for (S)-[18F]THK5117 
comparing WT and TG at 25m of age were analysed 
with Welsh’s t-tests. For all statistical analyses, the 
significance level was p < 0.05. 
Data availability 
The datasets generated during and/or analysed 
during the current study are available upon 
reasonable request. Request should be addressed to 
the corresponding author and data will be made 




The study of the University of Manchester cohort 
revealed that the TgF344-AD strain can easily be aged 
up to 18-19m but that, upon reaching this age, the rate 
of spontaneous illnesses or deaths start to increase 
due to spontaneous stroke, intracerebral or 
subarachnoid haemorrhage or tumours (Figure S1 
and Tables S1 and S4). The survival rate was not 
however significantly associated with genotype 
(p = 0.2748, Log-rank Mantel-Cox test; Figure S1). 
There was no statistical difference in body weights 
between the 2 cohorts of male rats (Tours and 
Manchester) presented in Table S2 and S3 (data not 
shown). 
Neuroinflammation and reactive gliosis 
detected by [18F]DPA-714 PET and 
immunohistochemistry are increased in the 
hippocampus, cortex and thalamus of aged 
Tg-F344-AD rats 
[18F]DPA-714 PET was performed to 
non-invasively assess longitudinal alterations in 
neuroinflammation in WT and TG rats at 
6 m, 12 m and 18 m (Figure 1). Data are 
presented as NUVCB as the uptake in 
cerebellum was not affected by genotype 
(Figure S4A). Both genotype and age 
significantly affected uptake in the 
hippocampus (genotype p = 0.001, age p 
< 0.001), frontal cortex (genotype p = 
0.010, age p < 0.001), thalamus (genotype; 
p = 0.002, age; p < 0.001) and 
retrosplenial/cingulate cortices 
(genotype p = 0.007, age p = 0.002). In the 
hippocampus, elevated uptake was 
observed in TG vs WT rats at 12 m (+11 ± 
8% p = 0.045) and 18 m (+12 ± 5% p = 
0.001) (Figure 1B). Additionally, 
increased uptake with age was seen in TG 
rats from 12 m (vs 6 m +13 ± 10% 
p = 0.008, 18 m vs 6 m +21 ± 7% p < 0.001, 
18 m vs 12 m +8 ± 9% p = 0.042) but only 
at 18 m in WT (vs 6 m +16 ± 7% p < 0.001 
and vs 12 m +7 ± 5% p = 0.001) indicating 
that hippocampal inflammation 
associated with normal aging is 
exacerbated in TG rats (Figure 1B). 
Similarly, [18F]DPA-714 uptake was 
significantly increased in TG when 
compared to WT rats at 18 m in the 
frontal cortex (+14 ± 7% p = 0.002), 
thalamus (+11 ± 7% p = 0.020) and 
retrosplenial/cingulate cortices (+7 ± 5% 
p = 0.024). 18F]DPA-714 signal was also 
increased with age in the retrosplenial/ 
cingulate cortices (+13 ± 9% 18 m vs 6 m, 
p = 0.003) in the TG group only (Figure 
 
 
Figure 1. (A) Representative averaged 20-60 min [18F]DPA-714 PET-CT images co-registered with the 
MR template. ROIs for the retrosplenial & cingulate cortices (RCgCx), thalamus (Thal) and hippocampus 
(Hipp) are shown in the top left (6 m, WT) image. The frontal cortex is not shown on the PET-CT images 
as this region is more rostral. (B) [18F]DPA-714 uptake quantification in various regions of the brain in WT 
(green circle symbols) and TgF344-AD (red square symbols) rats at 6, 12 and 18 months (m) of age. Data 
are expressed as mean ± SD of uptake values normalised to cerebellum. * and  indicate significant 
differences vs the 6 and 12 m old animals respectively and # indicates significant difference between WT 
and TG for rats of same age. *,  or # indicates p < 0.05, **//## p < 0.01 and ***//### p < 0.001. 
PET data were analysed using a mixed model (age as repeated factor and genotype) and a Sidak post-hoc 
test. 





1B). Moreover, [18F]DPA-714 uptake was only affected 
by genotype in the entorhinal and frontoparietal 
motor cortices (p = 0.042 and p = 0.046 respectively, 
Figure S4B). 
Additionally, an effect of age was also observed 
in both WT and TG in some of these regions. 
[18F]DPA-714 uptake was increased with age in the 
frontal cortex (WT 18 m vs 6 m: +12 ± 7% p = 0.003, TG 
18 m vs 6 m: +17 ± 12% p = 0.003) and thalamus (WT 
12 m vs 6 m: +18 ± 15%, p = 0.009, WT 18 m vs 6 m: 
+30 ± 16%, p = 0.001; TG 18 m vs 6 m: +24 ± 8% p < 
0.001, TG 18 m vs 12 m: +19 ± 14% p = 0.005) (Figure 
1B), indicating that these region are also affected by 
normal aging. 
In contrast, in temporal-auditory cortex, 
frontoparietal somatosensory cortex and striatum, a 
significant effect of age only was detected (p = 0.042, p 
< 0.001, p < 0.001 respectively) (Figure S4C). 
However, in the temporal-auditory cortex, this effect 
of age was most likely driven by the TG data with a 
trend for genotype effect (p = 0.0599) and a significant 
difference between WT and TG at 18 m (Figure S4C). 
In the striatum, an age effect was seen in both WT and 
TG with a significant increase in neuroinflammation 
at 12 m (+10-12%) and 18 m 
(+15-18%) (Figure S4C). In the 
hypothalamus, a significant 
interaction age × genotype (p = 0.01) 
was observed with a transient 
increase in [18F]DPA-714 uptake in 
TG only observed at 12 m (+26 ± 
18% vs 6 m, p = 0.007 and +24 ± 21% 
vs 18 m p = 0.049) and returning to 
baseline at 18 m (Figure S4D). 
Activated microglial and 
astrogliosis were quantified by 
CD11b and GFAP immunohisto-
chemistry labelling density at 6, 12 
and 18 m (Figure 2). Quantification 
of images revealed both age and 
genotype dependent increases in 
CD11b-positive cells in 
hippocampus (genotype p < 0.001, 
age p = 0.002, genotype × age 
interaction p = 0.006), frontal cortex 
(genotype p < 0.001, age p < 0.003, 
genotype × age interaction p = 
0.007), temporal cortex (genotype p 
< 0.001, age p = 0.004, genotype × 
age interaction p = 0.005) and 
thalamus (genotype p < 0.001, age p 
= 0.003). Markedly elevated CD11b 
staining (%stained area) was 
observed in TG rats vs WT in the 
temporal/cingulate cortices at 12 m 
and 18 m (+564 ± 28% and +383 ± 
33% respectively, both p < 0.001, 
Figure 2), and at 18 m in the 
hippocampus (+723 ± 44% p < 
0.001), frontal cortex (+435 ± 54% p < 
0.001) and thalamus (+115 ± 30% p = 
0.001) (Figure S5). Consistent with 
these results, increases in CD11b 
staining with age was also observed 
in TG rats in these regions which 
was not evident in the WT rats 
(Figure 2, Figure S5). 
 
 
Figure 2. Representative micrographs of microglial (CD11b, top panel) and astrocytes (GFAP, bottom panel) in 
the temporal/posterior cingulate cortices of WT and TG rats at 6, 12 and 18 months (m) of age. Quantification of 
the immunofluorescence expressed as percentage of area stained. * and  indicate significant differences vs the 6 
and 12 m animals respectively and # indicates significant difference between WT and TG for rats of same age. *,  
or # indicates p < 0.05, **//## p < 0.01 and ***//### p < 0.001. Data were analysed using 2-way ANOVA 
(age as repeated factor and genotype) and a Sidak post-hoc test. Scale bars represent 200µm. 





Astrogliosis (GFAP+) was found to be elevated 
in temporal/posterior cingulate (TG vs WT: 6 m: +99 
± 18%, p = 0.013; 12 m: +84 ± 27% p = 0.007; 18 m: +89 
± 38%, p = 0.004; Figure 2) and frontal cortex (TG vs 
WT 12 m: +109 ± 25% and 18 m: +98 ± 38% p < 0.001 
for both, Figure S5). In the thalamus, astrogliosis was 
increased in TG vs WT at 6 m (+158 ± 21%, p = 0.001) 
but decreased with age to reach similar levels as in 
WT (6 m vs 12 m: -44 ± 42%, p = 0.008, and 6 m vs 18 
m: -39 ± 32%, p = 0.007, respectively, Figure S5). In the 
hippocampus, there was a significant effect of 
genotype (p = 0.008) and a significant decrease with 
age at 18 m vs. 6 m in both WT (-47 ± 33%, p = 0.036) 
and TG (-36 ± 24%, p = 0.014, Figure S5). 
 
 
Figure 3. (A) Representative sum images (49-61 min) of [18F]-ASEM (α7 nicotinic 
receptor) PET-MR in the brain of WT and TgF344-AD rats at 6, 12 and 18 months (m) 
of age (pallidum/nucleus basalis of Meynert (NBM), striatum are respectively indicated 
with white, yellow * on the top right (WT 18 m) PET image). Quantification of the 
[18F]-ASEM uptake in pallidum/NBM (B) and striatum (C) of WT (green circle 
symbols) and TgF344-AD (red square symbols) rats. (B, C) Data are expressed as 
mean ± SD of uptake values (sum image 20-60 min) normalised to cerebellum. * and 
 indicate significant differences vs the 6 and 12 m old animals respectively and # 
indicates significant difference between WT and TG within age groups. *,  or # 
indicates p < 0.05. PET data were analysed using a 2-way ANOVA (age as repeated 
factor and genotype) and a Sidak post-hoc test. 
 
[18F]ASEM PET imaging indicates reduced 
subcortical α7-nAChR density in TgF344-AD 
rats 
Serial [18F]ASEM PET imaging was performed to 
assess α7-nAChR density as a marker of cholinergic 
function with disease progression in TG compared to 
WT rats. Explorations of α7-nAChRs has not 
previously been investigated in this model, thus 
[18F]ASEM PET was also performed at 6 m, 12 m and 
18 m (Figure 3A). Significant changes in [18F]ASEM 
signal were observed in the pallidum/nucleus basalis of 
Meynert (NBM), with a significant effect of genotype 
(p = 0.028) and an age × genotype interaction (p = 
0.017). Increased [18F]ASEM uptake was observed in 
this brain region with age in WT rats (12 m vs 6 m: +25 
± 33%, p = 0.031; 18 m vs 6 m: +27 ± 30%, p = 0.015), 
which did not occur in TG, resulting in the TG being 
significantly lower than the WT at 12 m (-15 ± 11% , p 
= 0.038) and 18 m (-15 ± 8%, p = 0.038) (Figure 3B). A 
similar effect was detected in the striatum (age effect p 
= 0.019) driven by a significant increase in tracer 
uptake only in WT animals (12 vs 6 m: +22 ± 32%, p = 
0.049; 18 m vs 6 m: +25 ± 29%, p = 0.012) (Figure 3C). 
There was a more modest increase with age in 
thalamus (age effect, p = 0.047; post-hoc 18 m vs 6 m: 
+10 ± 12% p = 0.045) (Figure S6A). In contrast, no 
significant differences were observed in cortex (Figure 
S6B) or hippocampus (Figure S6C-D). 
Amyloid deposition detected by 
[18F]Florbetaben PET and immunohisto-
chemistry is increased in hippocampus and 
cortex of TgF344-AD rats 
[18F]Florbetaben ([18F]AV-1) PET was conducted 
to assess levels of amyloid pathology in both 
genotypes at 6 m, 12 m and 18 m (Figure 4A-B). 
Analysis revealed a significant genotype effect in the 
cortex (p = 0.001) and genotype × age interaction in 
the dorsal hippocampus (p = 0.028), which resulted in 
increased uptake in TG compared to WT rats at 18 m 
in both regions (+15 ± 7% p = 0.012 and +12 ± 7% p = 
0.020 respectively) (Figure 4A-B). Increased tracer 
uptake was also observed at 18 m vs. 6 m in TG dorsal 
hippocampus (+13 ± 12% p = 0.005). Progressive 
amyloid burden was confirmed via 6E10 
immunohistochemistry (Figure 4C-D). No changes 
were observed in striatum and cerebellum, which are 
known to be less affected by Aβ pathology (Figure 
S7). Quantification of 6E10 immunofluorescence 
revealed a significant increase in amyloid plaques 
number from 6 m in cingulate cortex (+533 ± 47% at 12 
m and +813 ± 43% at 18 m vs 6 m p < 0.001; +44 ± 28% 
at 18 m vs 12 m p = 0.039), hippocampus (+364 ± 26% 
at 12 m and +446 ± 27% at 18 m vs 6 m p < 0.001), and 
later in thalamus (+321 ± 16% and +109 ± 35% at 18 m 
vs 6 m and 12 m, p < 0.001 and p = 0.003 respectively) 
(Figure 4C). Notably, the number of plaques in the 
thalamus was about 10 times lower than in cortex and 
hippocampus at all ages (Figure 3C). In addition to 





progressive amyloid deposition, increased plaque size 
(µm2) was also seen with age in cingulate cortex (+68 ± 
16% at 12 m and +49 ± 20% at 18 m vs 6 m, p < 0.001 
and p = 0.002 respectively), but not hippocampus or 
thalamus (Figure 4D). 
 
 
Figure 4. PET quantification (A) of [18F]Florbetaben uptake normalised to brain stem in the cortex and dorsal hippocampus of WT (green circle) and TG (red squares) rats and 
(B) representative PET-MR sum images (43-51 min) of [18F] Florbetaben brain uptake at 6, 12 and 18 months of age (In top left image, c and h denotes the position of the cortex 
and hippocampus respectively). (C) Quantification of the β-amyloid immunohistochemistry (6E10) in the cingulate cortex, hippocampus and thalamus of TG rats 6, 12 and 18 
months (m) of age. NOTE there are two (D) on figure. (D) Representative images of the β-amyloid immunohistochemistry (6E10) in the hippocampus of TG rats (scale bars 
represent 500 µm). Data are expressed as mean ± SD. * and  indicate significant differences vs the 6and 12 mold animals respectively and # indicates significant difference 
between WT and TG. *,  or # indicates p < 0.05, **//## p < 0.01 and ***//### p < 0.001. PET data were analysed using a mixed model, immunohistochemistry data were 
analysed using a 2-way ANOVA with age as repeated factor and genotype in both analysis and a Sidak post-hoc test. 






Figure 5. Tauopathy in the TgF344-AD rats as detected by in vivo by PET imaging (A), autoradiography (B) and immunohistochemistry (C). (A) PET data revealed an increase 
in [18F]THK5117 uptake in TG rats, mostly in hippocampal and cortical areas. (B) Ex vivo autoradiography revealed greater differences in Tau signal than PET in most cortical 
areas, the hippocampus, and a modest but significant increase in the thalamus. (C) Immunohistochemistry using AT8 anti-Tau antibody in 18 month (m) old TG rats revealed that 
Tau deposition (arrows) occurred only around amyloid plaques. PET and autoradiography data are expressed as mean ± SD. * and # indicate significant difference between 15 and 
25m old animals and between WT and TG, respectively. * or # indicates p < 0.05, **/## p < 0.01 and ***/### p < 0.001. PET data were analysed using a 2-way ANOVA (genotype 
and age) and a Sidak post-hoc test. Autoradiography data were analysed using a Welch’s t-test. (C) Scale bars represent 200 µm (top row) and 20 µm (bottom row). 
 
(S)-[18F]THK5117 PET and autoradiography 
detect increased Tau pathology, 
immunohistochemistry reveals that it is 
localized around amyloid plaques in 
TgF344-AD rats 
(S)-[18F]THK5117 PET was performed to detect 
Tau deposition at 15 m and 25 m (Figure 5A). 
Longitudinal analysis revealed a significant effect of 
genotype and/or age on tracer uptake in temporal- 
auditory cortex (genotype p < 0.001, age p = 0.020, age 
× genotype interaction p = 0.012), frontal cortex 
(genotype p = 0.012, age p = 0.001), piriform cortex 
(genotype p < 0.001) and hippocampus (genotype p = 
0.003), resulting in increased signal in TG vs WT rats 
in these regions (temporal-auditory cortex 15m: +11 ± 
3%, p = 0.006, 25 m: +24 ± 3%, p < 0.001; hippocampus 
25 m: +13 ± 3%, p = 0.019; piriform cortex 15 m: 17 ± 
4%, p < 0.001, 25 m: 15 ± 2%, p < 0.001, Fig, 5A; frontal 
cortex, 15 m: +9 ± 2%, p = 0.003 Figure S8A). Increased 
uptake was observed with age only in cingulate 
cortices (p = 0.016) and frontoparietal cortex (p = 
0.009). No significant difference was observed in the 
thalamus (Figure 5A), pons, cerebellum or 
hypothalamus via PET. 
High resolution in ex vivo autoradiography of the 
animals previously scanned with (S)-[18F]THK5117 at 
25m confirmed increased signal in TG rats in cortical 
areas: frontal:+39 ± 3%, p = 0.007; frontoparietal: +24 ± 
5%, p = 0.008; temporal: +48 ± 10%, p = 0.014) and 
hippocampal (+79 ± 12%, p = 0.023) regions (Figure 
5B). A moderate increase was also observed in the 
thalamus (+17 ± 4%, p = 0.012); however, in line with 
the in vivo PET results, no significant difference was 
detected in the cerebellum (Figure 5B). 
As gold-standard experiments to confirm 
(S)-[18F]THK5117 PET and autoradiography 
experiments, we performed immunohistochemistry 
using phospho-Tau AT8 (Figure 5C), CP13 and PHF-1 
(Figure S8B-C) anti-Tau antibodies and confirmed the 
presence of endogenous Tau hyperphosphorylated in 
various positions (AT8: Ser202+Thr205; CP13: Ser202; 
PHF-1: Ser396+Ser404) in hippocampus of TG but not 
WT rats at 18 m. Moreover, Tau pathology appeared 
to be localized around Thioflavine-S positive amyloid 
plaques in this model. Western blots of hippocampus 





and whole-cortex homogenates were not sensitive 
enough to detect a significant increase in Tau 
phosphorylation in TG rats (Figure S9); this is 
consistent with the phosphorylated Tau detected 
being restricted to the periphery of Aβ plaques by 
immunohistochemistry (Figure 5C, Figure S8) which 
will be diluted when working on homogenate of 
whole brain structures such as hippocampus or 
cortex. 
Neuronal loss in TgF344-AD rats is limited to 
regions occupied by Aβ plaques 
Despite extensive attempts to detect neuronal 
loss using NeuN immunohistochemistry by 
fluorescence or chromogenic methods, we only 
detected age-related neuronal loss in hippocampus 
(CA1), cingulate posterior and temporal cortices 
(Figure 6A-B, Figure S10) and thalamus (Figure S10A). 
We found no significant effect of genotype. However, 
we noticed an increase in autofluorescence in the cell 
body of the neurons with age, it is therefore possible 
that this transient increase in the number of NeuN+ 
cells might be a false positive, this motivated the use 
of the chromogenic method to avoid this issue for 
further investigations. 
The chromogenic method revealed only a 
non-significant trend of decrease in neuronal count in 
CA3 in TG at 18 m (-14% ± 12, p = 0.298) (Figure S11). 
Neutral red Nissl labelling of dentate gyrus, CA1 and 
CA3 produced similar results (data not shown). 
Using the pan-neuronal marker Neurochrom, we 
were however able to observe clear loss of neuronal 
staining in the space occupied by or even surrounding 
Aβ plaques (Figure 6C, Figure S10B), demonstrating a 
direct but very localised impact of Aβ plaques on 
neurons. Normal Neurochrom staining is 
characterised by a homogenous staining of the grey 
matter in which blood vessels (bv in Figure 6C) and 
lack of staining due to plaques appear darker (white 
arrows in Figure 6C). 
Absence of significant cognitive decline in 
TG rats may be masked by reduced locomotor 
activity in the Fischer strain 
Longitudinal NOR revealed a significantly 
longer exploration of the novel over the familiar object 
in the retention phase of the task in both WT and TG 
animals at both 3 and 6 m of age (Figure 7A), however 
neither WT nor TG animals demonstrated any 
preference for the novel object at 12 or 18 m of age 
(Figure 7A). Analysis of discrimination index (DI) 
over time did not reveal any significant differences 
between groups (genotype p = 0.093, age p = 0.283, 
interaction age × genotype p = 0.986, Figure 7B). Total 
exploration times in the retention phase of the NOR 
test was significantly reduced in both WT (12 vs 3 m: 
-14 ± 62% p < 0.0001; 12 vs 6 m: -63 ± 63% p = 0.006; 18 
vs 3 m: -68 ± 56 % p = 0.0002; 18 vs. 6 m: - 60 ± 57% p = 
0.0117) and TG rats (6 vs 3 m: -37 ± 41% p = 0.0267; 12 
vs 3 m: -67 ± 34 % p = 0.0002; 18 vs 3 m: -86 ± 47% 
p < 0.0001; 18 vs. 6 m: -77 ± 56 % p = 0.026) with age 
(Figure 7C). Similar results were found for total 
exploration time in the acquisition phase (Figure 
S12B). No significant differences were identified 
between the exploration of the left and right objects in 
the acquisition phase with either group at any age 
indicating no side bias (Figure S12C). In general, this 
reduced locomotor activity limits the interaction with 
objects in the NOR and may be masking any cognitive 
deficits between genotypes. 
Following our own observations in the NOR at 3 
and 6 m, we decided to investigate social interaction 
at 9, 12, 15 and 18 m by investigating sniffing 
behaviour of a conspecific WT animal, as well as 
quantifying the time of exploration of a central object. 
A reduction was observed in sniffing behaviour at 9m 
(Figure 7D) with TG rats spending less time sniffing 
and interacting with conspecific animals compared to 
WT (p = 0.001). However, there was no effect at other 
time points. No significant differences were seen in 
exploration of the central object between WT and TG 
rats at any time-point (9m p = 0.087; 12 m p = 0.905; 
15m p = 0.498; 18 m p = 0.203) (Figure S12D). 
AD-like pathology and normal aging affect 
regional brain metabolite profiles assessed by 
MRS 
MRS was performed in WT and TG rats at 6, 12 
and 18 m to assess metabolite profiles in the 
hippocampus (bilateral and right side), thalamus, 
hypothalamus and cortex (example spectra in Figure 
8A). An effect of age (p < 0.001) and an age × genotype 
interaction (p = 0.037) were observed with N-acetyl- 
aspartate (NAA) in the bilateral hippocampus, 
resulting in significantly reduced NAA levels in 18 m 
TG vs age-matched WT (-18 ± 14%, p = 0.042) and vs 
6 m TG rats (-31 ± 15%, p = 0.017) (Figure 8B). We did 
not observe alterations in NAA in other regions 
displaying high levels of Aβ plaques in this rat model 
such as the cortical voxel. 
The total of choline-containing compounds 
(tCho) in hypothalamus was affected at both age 
(p < 0.001) and genotype (p = 0.047), with a modest 
but significant reduction in WT rats at 12 m only (vs 6 
m: -12 ± 6%, p = 0.017). Similarly, tCho levels in right 
hippocampus were affected by age and genotype 
(interaction p = 0.002), with reduced tCho levels seen 
in TG vs WT rats at 6 m (-11%, p < 0.001) and with age 
only in WT animals (12 m vs 6 m: -13 ± 9%, p = 0.040; 
18 m vs 6 m: -16 ± 8%, p = 0.006, Figure 8B). In 





contrast, cortical Taurine levels increased in the cortex 
(age p < 0.001, interaction p = 0.047 and a trend for 
genotype p = 0.058), leading to significant increases 
with age in TG rats (18 m vs 6 m: +55 ± 22%, p = 0.007; 
18 m vs. 12 m: +37 ± 16%, p = 0.012) and in TG when 
compared to WT rats at 18 m (+35 ± 14%, p = 0.002). 
 
 
Figure 6. (A) Representative micrographs of NeuN staining in WT and TG rats at 6, 12 and 18 months (m) of age in the hippocampus CA1 (top panel) and temporal-cingulate 
posterior cortices (bottom panel) and (B) their respective quantification expressed as percentage stained area and number of NeuN positive cells/mm². There was no significant 
difference in NeuN staining between WT and TG and only a significant decrease due to age. Data are expressed as mean ± SD. * and  indicate significant differences vs the 6 
and 12 m old animals respectively. * or  indicates p < 0.05, **/ p < 0.01. Data were analysed using 2-way ANOVA (age as repeated factor and genotype) and a Sidak post-hoc 
test. (C) Representative micrographs of immunohistochemistry for pan-neuronal Neurochrom and β-amyloid in the hippocampus of TG rats at 6, 12 and 18 months (m) of age 
highlighting a clear loss of neuronal staining where β-amyloid plaques are present. Normal Neurochrom staining is characterised by a homogenous staining of the grey matter (bv 
= space occupied by blood vessels, negative for Neurochrom). Last panel on the right shows higher magnification of dotted line box of 18 m group with DAPI stain for the merged 
images. Yellow dotted lines highlight the loss of Neurochrom staining at the location of Aβ plaques. (A & C) Scale bars represent 200 µm. 






Figure 7. (A) Wildtype (WT) and transgenic (TG) rats displayed increased exploration of the novel object in the NOR retention phase at 3 and 6 months (m) but were unable 
to discriminate objects at 12 and 18 m of age (t-tests). Analysis of discrimination index (DI) over time did not reveal any significant differences between groups (genotype p = 
0.093, age p = 0.283, 2-way ANOVA mixed model repeated measure) (B). Total exploration times in the retention phase of the NOR test revealed significantly reduced active 
exploration of both WT and TG rats with age (1-way ANOVA) (C). TG rats spent decreased time sniffing con-specific animals than WT rats in the social interaction test, with 
a significant reduction observed at 9 m (t-tests). Data are expressed as mean ± SEM. + indicates significant difference vs. 3 m and * indicates significant difference vs. 6 m. +/* p 
< 0.05, **p < 0.01, +++/*** p < 0.001 and ++++/**** p < 0.0001. 
 
Additionally, some metabolites were affected by 
age alone in the thalamus (NAA p < 0.001; tCho p = 
0.003; glutamate p = 0.012), cortex (glutamate p < 
0.001), full hippocampus (Taurine p = 0.031) and 
hypothalamus (Taurine p < 0.001). However, some 
changes were driven by the TG data (Thalamus: 12 vs. 
6 m: NAA -16% p = 0.006; tCho -13 ± 9% p = 0.032; 
Cortex 12 m and 18 m vs 6 m: Glutamate +45 ± 20% p 
< 0.001 and +39 ± 22% p = 0.019, respectively) (Figure 
8C). Myo-inositol levels were not significantly altered 
at any time-point. 
Discussion 
Through the use of a multi-modal approach 
carried out independently in various labs, we 
demonstrate here that a comprehensive range of 
parameters, from cognition to brain pathological 
features, are altered in the TgF344-AD rat model. We 
report for the first time, longitudinally and in vivo, 
alterations of neuroinflammation, the α7 nicotinic 
receptor, amyloid burden, Tau pathology and brain 
metabolites using PET and MRS techniques in the 
TgF344-AD model of AD. It must however be noted 
that most ex vivo observations obtained here are 
similar to those seen in mouse models of AD. Hence 
the AD rat presents a model that is similar in most 
aspects to the transgenic mouse models but with the 
undoubted advantage of having a larger brain that 
allows application of a wide range of in vivo imaging 
techniques which are far less applicable to or less 





sensitive in mice. It must be noted however that the 
larger rat brain does not completely circumvent 
potential limitations of in vivo imaging such as partial 
volume effect, which may hamper quantification of 
PET signal in all species including humans especially 
when measuring small brain structures and/or subtle 
changes. Ultimately, in vivo imaging presents the 
advantages of being non-invasive, allowing 
longitudinal studies to explore various molecular 
targets in a same animal and is fully translational 
while ex vivo read-outs are the complementary, more 
sensitive, absolute gold standards in term of 
pathophysiology. 
Our findings support the use of imaging in such 
a rat model to monitor disease progression in vivo and 
investigate new therapies more sensitively than can 
be achieved with behavioural tests, which are harder 
to measure and may appear only at later stages. The 
changes we have observed in the TG rat model are 
also in good agreement with clinical observations, 
further supporting the use of this model to investigate 
AD. 
Neuroinflammation 
Evidence suggests that neuroinflammation has 
an integral role to play in AD development with 
reports of increased neuroinflammation early in 
clinical AD and MCI as well as in pre-clinical models 
[33, 49, 50]. Cohen et al. [12] detected a moderate 
increase in neuroinflammation using immunohisto-
chemistry as early as 6 m in the TgF344-AD rat model. 
Hence, we wanted to investigate if we could detect 
these in vivo using [18F]DPA-714 PET. Here, we 
observed increased [18F]DPA-714 uptake in the 
 
 
Figure 8. AD-like pathology and normal aging affect regional brain metabolite profiles. (A) Example MRS spectra obtained from the hippocampus of Wildtype 
(WT) and transgenic (TG) rats at 6 months (m) of age. The multiple peaks of metabolites of interest are labelled as: 1: N-Acetyl-aspartate, 2: Glutamate, 3: total Creatine 
(creatine + phosphocreatine), 4: tCholine, 5: Taurine, 6: myo-inositol. (B) Metabolites affected by age and genotype/age × genotype interaction. (C) Metabolites affected by age 
alone. * and  indicate significant differences vs the 6and 12 m old animals respectively and # indicates significant difference between WT and TG. *,  or # indicates p < 0.05, 
**//## p < 0.01 and ***//### p < 0.001. The concentration of metabolites presented are expressed in institutional units which relate to mMol/kg tissue wet weight, 
assuming a water content of 0.78 mL/g in rodent brain. MRS data were analysed using a mixed model (age as repeated factor and genotype) and a Sidak post-hoc test. Results are 
shown as mean ± SD. Note: brain region names in figure are written differently for some panels e.g. hipp. & hippocampus, Hypothal. & hypothalamus. 





hippocampus (12 m) and cortical areas and thalamus 
(18 m) of TG rats compared to WT rats. These results 
are in agreement with numerous previous TSPO PET 
study in mouse models of AD [26, 29, 51-56] and also 
the majority of clinical studies [33, 57-59] which 
reported similar (+10-30%) significant increase in 
TSPO tracer uptake mostly in regions affected by AD 
pathology (e.g. hippocampus, frontal and cingulate 
cortices). Interestingly, increased [18F]DPA-714 
binding was also seen with age in WT animals, 
suggesting increased inflammation occurs with 
normal aging. This is in line with findings of increased 
neuroinflammation with normal aging [60-62] as 
notably assessed by TSPO PET in in WT animals 
(+4-20%) [63, 64] as well as healthy subjects (+4.7~10% 
per decade) [65, 66]. Similarly, ex vivo analysis by 
immunohistochemistry demonstrated an early (6 m) 
modest presence of activated microglia/ 
macrophages, increasing sharply by 12 m and even 
further at 18 m in the hippocampus and cortical areas 
in TG. Increases in [18F]DPA-714 uptake was matched 
by increase in CD11b staining in most ROIs, except for 
the hippocampus at 12 m in which there was a trend 
to increase in CD11b (p = 0.098) and the temporal 
cortex in which the [18F]DPA-714 uptake was not 
significantly altered at 12 m. Various reasons such as 
difference in sensitivity of the methods and/or 
statistical variability are likely to have caused such 
discrepancies. Interestingly, and in agreement with 
our PET results, microglial activation was also found 
to be elevated in thalamus at 18 m, although more 
modestly than in the hippocampus and cortices, and 
in relation with the much lower amyloidosis (× 10 less 
in thalamus than hippocampus/cortices). Astrogliosis 
was also increased in TG vs WT but conversely to 
microgliosis, astrogliosis was elevated in TG at all 
ages and as early as 6 m but tended to decrease with 
age in both TG and WT. 
These results are altogether in agreement with 
our PET results and numerous previous reports 
showing increasing microglial activation with AD 
burden and age in various rodent models including 
the TgF344-AD rats [12, 26, 29, 63, 67-73]. Similarly, 
the decrease in astrocyte staining with age and/or 
progression of AD pathology observed here is 
consistent with previous reports that have 
demonstrated a complex regulation of astrocytes with 
age and disease with astrogliosis in disease combined 
with a decrease in astrocyte numbers and function 
with age [74-78]. 
Amyloid pathology 
Here we report the first longitudinal 
investigation of amyloid-PET in the TgF344-AD 
model. Using in vivo [18F]Florbetaben PET, we 
detected a significant cortical and hippocampal 
amyloid deposition in TG compared to WT rats at 18 
m (+12-15%) of age, similar to those detected in mice 
(+12~25%) at 18-20m of age [29, 63, 79, 80] but lower 
than those reported in clinical studies (+25~100%) [57, 
81, 82]. In support of this, immunohistochemical 
analysis revealed significant progressive amyloid 
deposition in cortical and hippocampal regions of TG 
rats starting from a sparse but significant amyloid 
deposition at 6 m progressing towards a heavy 
amyloid load at 12 m and 18 m of age. Our 
immunohistochemical results are in agreement with 
the initial report in this model [12]. However, amyloid 
PET was not able to detect significant increases at 12 
m in vivo, likely due to i) the limitations in resolution 
of small animal PET imaging, ii) the poor signal to 
noise ratio of amyloid tracers which are notoriously 
lipophilic and iii) 12 m being a relatively young age 
for the rats. In this regard, and compared to clinical 
amyloid PET scans, it must be considered that 6 m 
and 12 m are relatively young ages in rats which have 
a life-expectancy that can reach about 30m depending 
on the strain [83], although the TgF344-AD rats have 
been aged only up to 25m here (Turku) and up to 26 m 
in the literature [12]; so one may consider that these 
rats were imaged proportionally at younger than AD 
or MCI patients would. 
Tau pathology 
The TgF344-AD rat was reported by Cohen et al. 
[12] to be the first rodent model to exhibit 
spontaneous NFT-like hyperphosphorylated Tau 
accumulation similar to that seen clinically. Here we 
use (S)-[18F]THK5117 to investigate longitudinally the 
Tau burden in vivo. We observed significant increase 
in (S)-[18F]THK5117 uptake in cortical and 
hippocampal regions TG rats when compared to 
age-matched WT rats mostly at 25m of age. Ex vivo 
autoradiography supported these findings and 
revealed markedly elevated binding in regions known 
to be affected in AD including the frontal cortex, 
hippocampus and thalamus. These results are 
somehow in contradiction with the Tau biochemistry 
analysis performed by Cohen et al. [12] which 
demonstrated increased Tau level earlier, at 6 and 16 
m, but no further increase at 26 m, however this is 
most likely due to the methodological approaches 
being very different (in vivo or ex vivo isotopic 
methods vs Western blots). However, our 
immunohistochemical analysis identified Tau 
hyperphosphorylation in the hippocampus at 18 m in 
agreement with previous studies [12, 28]. Our 
immunohistochemical analysis also revealed that 
hyperphosphorylated Tau was found only in 
dystrophic neurites around the amyloid plaques in 





the TG rats. This is in agreement with the potential 
seeding of Tau pathology by Aβ [84] and observations 
by Cohen et al. [12] and also Morrone et al. [19] who 
reported that 80-85% of PHF1+ neurons were located 
near Aβ plaques. This observation is however in 
contrast to Tau burden reported also in non-plaque 
regions of the cortex and hippocampus [12, 28]. Those 
differences between studies may potentially be 
related to differences in the methods used and/or 
ages studied here and in other studies. The differences 
between the results of in vivo Tau PET and 
immunohistochemistry are likely to be explained by 
the lower sensitivity of PET and by the previously 
reported off-target binding of (S)-[18F]THK5117 [85, 
86]. Such off-target binding, notably to monoamine 
oxidases, has been a major problem to most 
first-generation Tau tracers [87, 88]. The results 
presented here clearly confirms that off-target binding 
of Tau tracers may hamper detection of Tauopathy, 
and although second generation of Tau tracers have 
shown negligible monoamine oxidase binding [88, 
89], binding to other molecules such as neuromelanin 
and melanin still present a challenge to development 
of a Tau-specific PET tracer [87, 90, 91]. It is generally 
accepted that hyperphosphorylated Tau or NFT are 
absent or extremely difficult to detect in the mouse 
models with identical transgenes, although in some 
models, modest levels of hyperphosphorylated Tau 
have been reported [92]. Some PET studies using 
other tracers have successfully imaged Tau 
accumulation in transgenic Tau mouse model, and it 
is possible that using one of the new Tau PET tracers 
may show in vivo tau accumulation in the TgF344-AD 
rats at earlier time-points. Conversely, the levels of 
Tau deposition in this model have now been 
consistently reported by us and others [12, 19, 28], 
suggesting that this rat model reproduces this 
essential feature of AD. Moreover, the 3R to 4R Tau 
ratio in rats is similar to humans, but different to mice. 
Similarly to this model, the APP × PS1 rat model 
generated by Flood et al. [93] displayed dense fibrillar 
Aβ plaques with phosphorylated Tau in close 
proximity. Conversely, in the McGill-R-Thy1-APP 
model generated by Leon et al. [94], no neuronal loss 
or NFT-like Tau pathology were reported despite 
displaying amyloid pathology, cognitive deficits, and 
increased neuroinflammation. 
Neurodegeneration 
Here, and despite using 2 different methods of 
immunostaining for NeuN, we were not able to detect 
a significant decrease in numbers of neurons between 
WT and TG, contrary to the initial report on the 
TgF344-AD rats [12]. We however detected a 
significant decrease in NeuN percentage-stained area 
with age in both WT and TG in hippocampus, 
posterior cingulate/temporal cortices and thalamus at 
18 m of age, which may have contributed to the lack of 
differences between WT and TG at this age. Since the 
publication of the initial characterisation of the 
TgF344-AD strain, reports regarding neuronal 
loss/neurodegeneration have produced mixed 
results. Leplus et al. [95] detected loss of neurons in 
the gyrus dentatus and the cortex but not in CA1 using 
18 m old animals, whereas Voorhees et al. [96] 
reported neuronal loss in the hippocampus and not in 
the cortex at 24m of age. Voorhees et al. [96] noted that 
NeuN staining could produce false negative following 
the phagocytosis of neuronal debris by microglia and 
had to rely on cresyl-violet staining. Our results are 
however in line with those independently produced 
by our collaborators Anckaerts et al. [22] who did not 
detect any significant loss of neurons by NeuN 
immunostaining in female TgF344-AD at 10 and 20m 
of age. We however confirmed using Neurochrom 
staining that amyloid plaques create a void of viable 
neurons around them (Figure 6C and Figure S9B). 
This, in itself, is likely to disturb neuronal functions 
and connectivity. This hypothesis of very localised 
neuronal disruption fits well with our MRS findings 
showing decreased levels of NAA in the 
hippocampus, the presence of hyperphosphorylated- 
Tau positive neurons around the Aβ plaques shown 
here and the previously reported decrease in 
connectivity by rsfMRI [22, 23, 97]. Subtle localised 
neuronal alterations are also in agreement with other 
reports showing a decrease in glutamic acid 
decarboxylase positive neurons in CA1 [13], and in 
norepinephrine transporter and dopamine 
β-hydroxylase positive fibres in the hippocampus and 
gyrus dentatus respectively, without gross neuronal 
loss in the locus coeruleus [28]. In line with these 
changes in specific neurotransmission systems, we 
here demonstrate that there is significant 
age-dependent increase in α7-nAChR in the striatum 
and pallidum/NBM in WT, which does not occur in TG. 
It is noteworthy that our imaging study of α7-nAChR 
performed for the first time longitudinally in rodents 
is consistent with a human PET study that revealed an 
increased uptake of [18F]ASEM according to age in 
various brain regions including the striatum [98]. This 
apparent adaptation to aging, not occurring in TG, 
leads to a significantly lower level of α7-nAChR in TG 
at 18 m in the pallidum/NBM, which, if it had been 
taken in isolation, may have been considered as a 
decrease in TG rats. One may also consider that the 
changes attributed here to the pallidum/NBM may 
actually reflect changes occurring more specifically in 
the NBM (substantia innominata) principal efferent 
cholinergic structure in the rat brain and which was 





included in this larger ROI because the size of the 
NBM alone is beyond the resolution of PET and 
because of its close proximity with the globus pallidus 
[99]. It is particularly relevant to consider this in light 
of previous reports showing alterations of cholinergic 
receptor density in the striatum and thalamus which 
have been reported in AD [100-104]. 
We thus brought here new evidence of the 
involvement of the cholinergic system during aging 
and their dysfunction in AD, hence further 
supporting its interests as therapeutic target in AD. In 
particular, the involvement of α7-nAChR in this 
context may suggest this family of receptors as a 
potential target in AD [105-107]. Overall, this strongly 
supports the need for longitudinal in vivo 
multimodality investigations of the cholinergic 
system in animal models, as well as clinical settings to 
fully understand the changes in both ACh and its 
receptors in AD. In particular, the measurement of 
ACh levels in the basal forebrain in animal models 
and should be considered in future investigations. 
Behaviour 
Cognitive deficits in the TgF344-AD model have 
been previously reported from 6 m in the Barnes maze 
and at 13 m [19] and 24m using NOR [12]. Here, we 
assessed NOR at the earlier time-points of 3 m, 6 m, 12 
m and 18 m. At both 3 and 6 m, we did not observe 
significantly reduced performance in these rats 
suggesting there is no cognitive decline in TG 
compared to WT rats at these ages. However, we did 
observe reduced locomotor activity in both WT and 
TG rats from 12 m, which reduced their ability to 
perform the task. We observed deficits in social 
interaction at 9m of age with no changes at other time 
points. These results suggest that i) subsequent 
time-points between 18 m and 24m and ii) more 
refined tests, such as Morris water maze (MWM) and 
reversed-MWM [28] or delayed non-matching-to- 
sample task [23, 97], might be better suited to 
investigate the TgF344-AD rats. However, even with 
more sophisticated tests the cognitive deficits 
observed in TgF344-AD when compared to WT at 
various ages remain modest [23, 28, 97] requiring a 
thorough analysis of all parameters recorded [21] in 
order to observe significant differences. Reduced 
locomotor activity has previously been reported in 
Fischer male rats compared to other strains [46, 108] 
and could affect the ability of the rats to perform the 
NOR test. The fact that the same rats were monitored 
longitudinally at various age in the same environment 
may also explained a certain lack of motivation to 
perform the tests, although rats were exposed to 
totally new objects in the NOR tests and new 
conspecific animals for the social interaction test at 
each time-points. Altogether, our results are 
nevertheless in line with previous reports showing 
low motor activity [109], and anxious–depressive-like 
behaviour in the TgF344-AD [110]. The previously 
reported anxiety of the Fischer-344 strain [45, 46, 111] 
coupled with reduced locomotion in both WT and TG 
animals experienced here suggests that back-crossing 
transgenic rats generated on a Fischer-344 
background in another strain such as Wistar or 
Lister-hooded should be considered when 
behavioural parameters are particularly important 
read-outs. 
Metabolite alterations 
MRS permits the non-invasive detection of 
biochemical changes in vivo, allowing potential 
identification of changes in regional brain metabolites 
prior to anatomical or disease manifestation. We here 
report the first MRS investigation of the TgF344-AD 
rats. We notably observed alterations in hippocampal 
NAA and tCho, and cortical Taurine levels between 
genotypes with age. Interestingly, decreased 
hippocampal NAA levels were observed in TG but 
not in WT rats with age. NAA has long been 
considered as a marker of neuronal density [112], 
though it may better be described as a marker of 
neuronal function [112-115]. Therefore, decreased 
NAA levels are indicative of neuronal/brain 
dysfunction, hence our results suggest that 
hippocampal neuronal dysfunction occurred with age 
and worsened in the presence of AD-like pathology in 
TgF344-AD rats. This is consistent with multiple 
reports of decreased hippocampal NAA levels in AD 
and MCI patients [116-123], and in mouse models of 
AD [124-127] including our recent study using a 
mouse model [26] with the same mutations as the 
TgF344-AD rat [26]. Similar changes in NAA were 
also observed in the other TG rat model of AD 
McGill-R-Thy1-APP at 3 m or 9m of age [128, 129]. 
In the hippocampus, tCho decreased with age in 
WT but not in TG; TG animals had however 
significantly lower level of tCho than WT at 6 m 
suggesting an early alteration of tCho in TG with no 
further changes with age. Decreased tCho levels have 
also been reported in AD patients [117] but results are 
inconsistent with others reporting no significant 
changes [120]. In animal models of AD, levels of 
choline compounds were also decreased at 3 or 9m of 
age in McGill-R-Thy1-APP rats [128, 129]. Conversely, 
Esteras et al. [130] and Forster et al. [131] found 
increased levels of tCho in AβPP/PS1 and TASTPM 
mice respectively, whereas we did not find any 
significant change in APPswe × PS1∆9 mice [26]. Free 
choline is needed for the production of the 
neurotransmitter acetylcholine [132], so a decrease in 





tCho level may suggest reduced choline availability 
for acetylcholine synthesis. However, since free 
choline is only a minor component of the tCho peak (< 
10% [133]), this interpretation has to remain 
speculative. 
Myo-inositol has been suggested to be a glial 
specific marker and that increasing levels may be 
indicative of microglial activation or gliosis [116]. In 
this context, one could hypothesize an increase in 
myo-inositol in the TgF344-AD rat similarly to the 
transient (12 m) increase in myo-inositol reported in 
McGill-R-Thy1-APP rats [129]. However, despite 
increased neuroinflammation and amyloid pathology 
demonstrated in this model by this study and 
previously [12], no significant differences in 
myo-inositol levels were identified at any time-point. 
Again, previous findings using other models 
produced different results, we did not observe any 
change in myo-inositol in APPswe × PS1∆9 mice [26] 
whereas Forster et al. [131] found a robust increase in 
myo-inositol levels in the more aggressive TASTPM 
mouse model. However, the notion that myo-inositol 
is a glial marker is based on a single published report 
by Leibfritz and Brand [134] and a link with gliosis 
has never been further solidified. Furthermore, recent 
studies have questioned the association between 
myo-inositol and neuroinflammation while a 
correlation with amyloid burden has been reported 
[116]. 
On the other hand, we did see increased Taurine 
in TG rats. Taurine is an essential amino-acid known 
to have numerous functions such as osmoregulatory, 
neurotrophic and neuroprotective roles and excess or 
deficiency of Taurine levels leads to several diseases 
[135-138]. Taurine has also previously been shown to 
protect against excitotoxicity induced by amyloid 
[139], therefore the increase we observed in the cortex 
of TG rats at 18 m may be a compensatory protective 
mechanism to counter the amyloid-induced damages. 
In the hippocampus and hypothalamus, the increase 
in Taurine levels was driven by age suggesting a 
potential compensation to also counter aging 
processes. Our results are in line with increases in 
Taurine reported at 9 and 12 m of age in 
McGill-R-Thy1-APP rats [129] but have not been 
recapitulated in mouse models [26, 131]. 
Multiple regional metabolite alterations were 
identified with aging alone. This is in accordance with 
previous reports in both preclinical models [26, 129] 
and humans [140, 141], and highlights the need to 
better characterize the effects of normal aging to 
enable accurate measure of AD-specific alterations. 
Moreover, while MRS seems to be a valid tool to 
assess metabolite levels in vivo, the complexity of the 
analysis, differences in quantification methods (such 
as normalisation to water, total metabolites or 
creatine) as well as difficulties related to the size of the 
mouse brain when compared with rats and even more 
so between rodents and human may explain some of 
the discrepancies observed between studies. This 
highlights the need for further investigations 
combining in vivo MRS and PET with various ex vivo 
techniques such as mass-spectrometry to measure 
small metabolites and further understand their role in 
AD pathology. 
Conclusions 
Altogether our results provide an extensive 
review of the AD-like pathology and phenotype of the 
TgF344-AD rats model from early to advanced stage 
of the disease which is important to characterise for 
understanding disease progression and for testing 
new treatments. Our results show here, for the first 
time, interesting characteristics in term of altered 
metabolites by MRS, alongside quantification of 
α7-nAChR, Tau, Aβ and neuroinflammation by in vivo 
PET imaging confirmed by ex vivo analysis. Hence, 
providing a full, multi-modal characterisation of this 
model from early age (6 and 12 m) up to a more 
advance stage (18 m). The overall results of this study 
are summarised in Table 1. This study was made 
possible only through extensive collaboration 
between many labs. We would like to note however 
that a true multi-centre study, implying repeating 
similar experiments in different institutions, would be 
needed to investigate variability of data collection 
within each technique and provide added robustness 
to the results. Although it must be acknowledged that 
such study would significantly increase the financial 
cost as well as the ethical cost in term of number of 
animals used. Such characterization is essential before 
further studies, which are both time-consuming and 
expensive, could be reasonably undertaken using this 
model. The data provided here support the potential 
of this model to investigate mechanisms of AD 
pathology and new therapeutics with the significant 
advantage of the rat larger brain, which allows more 
precise quantifications in in vivo longitudinal imaging 
studies, when compared to mice. 
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Table 1. Summary of the study findings 
 
The age in months (m) at which each parameter (in rows) was assessed is indicated in columns. Changes found at these time-points: a grey shading indicate that there was no 
assessment of the parameter shown in the corresponding row, a white shading indicates that the parameter was assessed but no significant change were found, a blue or red 
shading indicate respectively a significant decrease/lower values or increase/higher values in the TG vs age-matched WT. Brain areas where the significant changes were 
detected are indicated in each cell (abbreviations: α7-nAChR = α7 nicotinergic acetyl-choline receptor; Autoradiog. = autoradiography; ThioF-S = thioflavine-S; NOR = novel 
object recognition test; Soc. Interact. = social interaction behavioural test; Thal. = thalamus; Hipp. = Hippocampus; Temporal Cx. = temporal cortex; Front. Cx = frontal 
cortex; Cx. = all neorcortical areas). * For MRS, the regions of interest correspond to the voxel shown Figure S2. 
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